AdaptResponse

Project

AdaptResponse

Completed · 2016 until 2022

Ammann Peter, Vetsch Susanne

Type

Clinical Studies

Range

Multicentric, KSSG as participating partner

Units

Kardiologie

Status

Completed

Start Date

2016

End Date

2022

Financing

Industry

Study Design

Following enrollment and baseline assessment, eligible subjects will be implanted with a CRT system containing the aCRT algorithm and randomized in a 1:1 fashion to either treatment (aCRT ON) or control (aCRT OFF) groups. Study subjects will be followed for a minimum of 24 months or until study closure, whichever comes first. Refer to the figure below for an overview of the study design

Brief description/objective

The AdaptResponse study is a prospective, randomized, controlled, interventional, single-blinded, multi-center, post-market, global Cardiac Resynchronization Therapy (CRT) in heart failure (HF) clinical study.

The purpose of this clinical study is to test the hypothesis that market released CRT devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal AV conduction and left bundle branch block (LBBB).